In January 2021, Hospitality Health ER began using bamlanivimab (BAM), a neutralizing antibody treatment for COVID.   

Our medical team has been at the forefront of early onset COVID-19 mitigation, and we are grateful to announce that our 3 locations are stocked with this highly beneficial treatment.   When a COVID-19 positive patient arrives at any of our facilities, the medical team will consider their need for a BAM infusion, alongside our multi-faceted COVID-19 response.  Highly effective in reducing the need for hospitalizations when delivered during the initial week of infection, BAM is reserved for medically at-risk populations.   Treatment can begin immediately in our facility, and patients are then kept for several hours of observation.   Additional information about BAM for COVID-19 treatment follows:

• The same class of treatment President Trump received for COVID-19 in Oct 2020.
• Produced by Eli Lilly, the antibodies are derived from recovered COVID patients.
• BAM has been authorized for emergency use by FDA.
• Our bodies naturally take 7-10 to produce antibodies to combat the virus.
• This treatment is approved for patients who fit the medical criteria and are over the age of 12.
• We have treated members of our own medical staff with BAM with rapid recovery outcomes.
• This treatment is currently only available via infusion clinics and in-patient hospitals,  following a multi-day, patient driven approval process.